Sanofi

SNY

Drug Manufacturers - General · Healthcare

Price

$44.66

+0.45 (+1.02%)

Market Cap

$107.37B

Exchange

NASDAQ

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Share count falling — buybacks

−2.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 2.50B (2021) → 2.44B (2025)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines

Winston Score History

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on SNY in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-11.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$7.8B/ year

↑ Rising (+6% vs prior year)

16.8% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

9.5%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$5.5B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Sanofi is putting 17% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

72.1%

Premium pricing power — 72.1% gross margin

Operating Margin

20.2%

Excellent — 20.2% operating margin

ROCE

2.5%

Weak — 2.5% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+8.2%

Steady sales growth (8.2% YoY)

EPS YoY

-27.9%

Earnings shrinking (-27.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

123%

Turns 123% of profit into real cash

FCF Margin

13.9%

Converts sales into free cash efficiently (13.9%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.25

Conservative — low debt load (0.25)

Interest Cover

12.51x

Comfortably covers interest (12.5x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

23.0x

Growth-priced — P/E 23.0

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+14.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (23.0 → 8.6)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

5.49%

Healthy income — 5.49% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend Growth

+49.4%

Dividend growing fast (49.4% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial